Compare Sana Biotechnology Inc (SANA) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vistra Corp — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Vistra Corp trades at $161.07 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 62.6× Sana Biotechnology Inc's market cap, and Vistra Corp pays a 0.59% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vistra Corp for 32 Days on average.
| SANA | VST | |
|---|---|---|
Market Cap | $836.71M | $52.41B |
Volume | 4,507,444 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $5.92 | $210.85 |
52-Week Low | $2.68 | $134.71 |
Typical Hold Time | 23 Days | 32 Days |
Enterprise Value | $749.96M | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Vistra Corp. (VST) trades at $160.84, down 3.53% over the past day, amid mixed quarterly earnings but strong analyst support. The stock shows a bullish technical trend with support at $152 and resistance at $164, while fundamentals reflect robust profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan to expand nuclear power output and a 20-year power supply agreement with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook remains positive given Wall Street's consensus price target of $215.23, implying 34% upside, though risks include earnings volatility and high valuation multiples. Investment appeal hinges on execution of growth initiatives in nuclear and data center power markets, with institutional confidence underscored by Peter Thiel's significant stake.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
